Hamburg, Germany, 04 January 2019: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that its partner Forge Therapeutics ("Forge") has received a second award from CARB-X (Combating Antibiotic Resistant Bacteria) for developing a novel antibacterial therapeutic agent. The award commits initial funding up to $ 5.7 m to Forge with the possibility of up to another $ 5.4 m based on the achievement of technical milestones. 

For further information, please follow this link to Forge’s full press release: www.forgetherapeutics.com/media/ 

About Evotec and Forge Therapeutics 

In December 2016, Evotec entered into a strategic alliance with Forge to accelerate its novel Gram-negative antibiotic programme. The alliance focuses on lead optimisation with the goal of identifying a development candidate in the next couple of years. 

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.